Daniel Solomon

Dr. Daniel Solomon

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in JAMA
Verified
Journal Article
Open access
PDF file
DSDaniel Solomon
Daniel Solomon
ASAmy C. Sherman
Amy C. Sherman
SKSanjat Kanjilal
Sanjat Kanjilal
This JAMA Insights Clinical Update emphasizes the importance of flu vaccination and nonpharmacologic public health interventions as key to managing the likely i

28 March 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SZSarah Zambrano
Sarah Zambrano
MPMolly L Paras
Molly L Paras
JSJoji Suzuki
Joji Suzuki
JPJeffrey C Pearson
Jeffrey C Pearson
BDBrandon Dionne
Brandon Dionne
DSDaniel Solomon
Daniel Solomon
Dalbavancin has been used off-label to treat invasive bacterial infections in vulnerable populations like people who use drugs (PWUD) because of its broad gram-positive coverage and unique pharmacological properties. This retrospective, multisite study examined clinical outcomes at 90 days in PWUD versus non-PWUD after secondary treatment with dalbavancin for bacteremia, endocarditis, osteomyelitis, septic arthritis, and epidural abscesses. Patients at 3 teaching hospitals who received dalbavancin for an invasive infection between March 2016 and May 2022 were included. Characteristics of PWUD and non-PWUD, infection highlights, hospital stay and treatment, and outcomes were compared using χ2 for categorical variables, t test for continuous variables, and nonparametric tests where appropriate. There were a total of 176 patients; 78 were PWUD and 98 were non-PWUD. PWUD were more likely to have a patient-directed discharge (26.9% vs 3.1%; P < .001) and be lost to follow-up (20.5% vs 7.14%; P < .01). Assuming loss to follow-up did not achieve clinical cure, 73.1% of PWUD and 74.5% of non-PWUD achieved clinical cure at 90 days (P = .08). Dalbavancin was an effective treatment option for invasive gram-positive infections in our patient population. Despite higher rates of patient-directed discharge and loss to follow-up, PWUD had similar rates of clinical cure at 90 days compared to non-PWUD.

1 July 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
DSDaniel Solomon
Daniel Solomon
ABAlison M Beieler
Alison M Beieler
SLSera Levy
Sera Levy
EEEllen F Eaton
Ellen F Eaton
MSMonica K Sikka
Monica K Sikka
SDShireesha Dhanireddy
Shireesha Dhanireddy
Injection-related infections require prolonged antibiotic therapy. Outpatient parenteral antimicrobial therapy (OPAT) has been shown to be feasible for people who inject drugs (PWID) in some settings. We report a national survey on practice patterns and attitudes of infectious diseases clinicians in the United States regarding use of OPAT for PWID.

18 October 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
EGEric Gillett
Eric Gillett
MAMuneerah M Aleissa
Muneerah M Aleissa
JPJeffrey Pearson
Jeffrey Pearson
DSDaniel Solomon
Daniel Solomon
DKDavid W Kubiak
David W Kubiak
BCBrian T Chan
Brian T Chan
Background: Current vancomycin monitoring guidelines recommend monitoring 24-hour area under the concentration-time curve (AUC) to minimum inhibitory concentration ratios for patients with serious methicillin-resistant Staphylococcus aureus infections. However, there are sparse data on the safety, feasibility, and efficacy of vancomycin AUC monitoring for outpatients. Traditional AUC pharmacokinetic calculations require 2 concentrations, while bayesian software allows for single-concentration AUC estimations. Methods: We conducted a single-center, quasi-experimental, interrupted time series study of patients enrolled in the outpatient parenteral antimicrobial therapy program at our institution for vancomycin management. Our institution implemented a pharmacist-driven vancomycin AUC monitoring program from September 2019 to February 2020, and again from September 2022 to March 2023. Patients enrolled underwent vancomycin monitoring using an AUC goal of 400–600 mg⋅h/L, estimated through bayesian modeling. Patients enrolled in the outpatient parenteral antimicrobial therapy program from July 2021 through August 2022 for trough-based monitoring were used for comparison. The primary outcome was nephrotoxicity incidence, defined as a serum creatinine increase by ≥0.5 mg/dL or ≥50% during outpatient vancomycin therapy. Results: We enrolled 63 patients in the AUC group and 60 patients in the trough-based group. Nephrotoxicity was significantly lower in the AUC cohort (6.3% vs 23.3%; P = .01). The number of unusable vancomycin concentrations was also significantly lower in the AUC cohort (0% vs 6%; P < .01). There was no difference in composite 90-day all-cause mortality or readmission (33.3% vs 38.3%; P = .56). Conclusions: Following implementation of a pharmacist-driven AUC monitoring program, patients were less likely to develop nephrotoxicity during outpatient vancomycin therapy.

12 April 2019 in Current Infectious Disease Reports
Verified
Journal Article
Closed access
PDF file
DBDaniel L. Bourque
Daniel L. Bourque
DSDaniel Solomon
Daniel Solomon
PSPaul E. Sax
Paul E. Sax

31 May 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
AEAhmed D Elnaiem
Ahmed D Elnaiem
ACAnand B Chukka
Anand B Chukka
CSCynthia M So-Armah
Cynthia M So-Armah
MAMaryCatherine E Arbour
MaryCatherine E Arbour
CHChuanchin Huang
Chuanchin Huang
CYChase G Yarbrough
Chase G Yarbrough
Background: Hepatitis C virus (HCV) disproportionately affects racial minorities and socially disadvantaged groups in the United States. Despite highly effective direct-acting antiviral (DAA) therapies, treatment disparities persist. Methods: We conducted a retrospective cohort study using electronic medical record data from both inpatient and outpatient settings in an urban academic medical center between 1 October 2018 and 1 October 2023. Multivariable logistic regression identified sociodemographic and clinical predictors of HCV treatment initiation, defined as a documented direct-acting antiviral prescription, among individuals with positive HCV RNA between 2018 and 2023. Results: Among 4345 individuals, 1150 (26.5%) were prescribed HCV treatment. Black individuals were less likely to be prescribed HCV treatment compared to White individuals (adjusted odds ratio [aOR], 0.68 [95% confidence interval {CI}, .53–.88]). Individuals experiencing homelessness (aOR, 0.57 [95% CI, .46–.69]) and those with Medicaid (aOR, 0.82 [95% CI, .68–.98]) or no insurance (aOR, 0.49 [95% CI, .37–.65]) were also less likely to be prescribed HCV treatment. Individuals with mental health diagnoses (aOR, 1.34 [95% CI, 1.11–1.61]) were more likely to receive HCV treatment. Untreated individuals had a higher percentage of inpatient (12.3%) and emergency department visits (17.7%) than those who received treatment (3.4% and 4.8%, respectively). Conclusions: Significant disparities in HCV treatment initiation were observed, with lower rates among Black individuals, those experiencing homelessness, and individuals with Medicaid or no insurance. These inequities perpetuate a disproportionate burden of liver disease and preventable mortality in already marginalized populations.